Safety, Regulation & Compounded Peptides
503A vs 503B vs research-only — what the FDA actually says.
What's covered
Click any topic to expand a deeper drill-down with mechanism, key references, and a take-home summary.
By the end of this module you will be able to
- L01Explain the 503A/503B distinction.
- L02List which 'longevity peptides' the FDA removed from compoundable bulk lists in 2023.
- L03Draft an informed-consent framework for compounded peptide therapy.
What you should walk away believing
Click any takeaway to open a full AI-generated lesson with mechanism, examples, evidence grading, counseling scripts, pearls, references, and a self-check.
What this means for you
Most 'wellness peptides' sold by clinics today were specifically flagged by the FDA as not safe for compounding pharmacies to make. The clinic may still offer them — but that doesn't make them legal or safe.
Know your category-1 vs category-2 list. Document consent including: regulatory status, absence of FDA approval, lack of human RCTs, sourcing/purity uncertainty, and reasonable alternatives.
USP 797/800 enforcement, state board of pharmacy actions, and DEA scheduling moves are the practical pressure points; expect continued enforcement post-2024 GLP-1 shortage resolution.
What the data say
Apply it
A 38-year-old recreational athlete brings you a printed protocol from a 'longevity clinic' for SC BPC-157 250 mcg BID for 4 weeks for chronic Achilles pain. Asks if you'll monitor labs and 'co-manage'.
- A.Agree to co-manage; it's compounded, so it's fine
- Decline to monitor and explain why: BPC-157 is FDA category 2, not approved, the clinic's product has no purity oversight, and routine 'monitoring' lends false legitimacy
- C.Refer immediately to FDA
- D.Order CBC/CMP and proceed
Test yourself
Lock it in — review what's due
Key terms & abbreviations
- 503A
- Compounding pursuant to a patient-specific prescription, by a state-licensed pharmacy.
- 503B
- Outsourcing facility registered with FDA, may compound without patient-specific Rx, must meet cGMP-like standards.
- Category 1/2/3
- FDA bulks-list classifications for substances proposed for compounding.
Sources cited in this module
- [1]World Anti-Doping Code Prohibited List 2025WADA · 2025Regulatory · T1
- [2]Medications containing semaglutide marketed for type 2 diabetes or weight lossU.S. FDA Drug Safety Communication · 2024Regulatory · T1
- [3]Category 2 list — bulk drug substances under 503A (includes ipamorelin, CJC-1295, BPC-157)FDA Pharmacy Compounding Advisory Committee · 2023Regulatory · T1
- [4]Compounding and the FDA: Questions and AnswersU.S. FDA · 2023Regulatory · T1
- [5]ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA OriginFDA Guidance for Industry · 2021Regulatory · T1
- [6]CDER/CBER classification: peptides ≤40 aa regulated as drugsU.S. FDA Federal Register Notice · 2020Regulatory · T1
- [7]Changes in moles linked to use of unlicensed 'sun tan jab'Langan EA. et al. · BMJ · 2009Case series · T3